 |
| Research article summary (published 29 Apr 2002): |
|
Free Full Text! See links below |
Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine.
Full Abstract
BACKGROUND:
The state of the brain reward system in major depressive disorder was assessed with dextroamphetamine, which probes the release of dopamine within the mesocorticolimbic system, a major component of the brain reward system, and produces measurable behavioral changes, including rewarding effects (eg, euphoria). We hypothesized that depressed individuals would exhibit an altered response to dextroamphetamine due to an underlying brain reward system dysfunction reflected by anhedonic symptoms.
METHODS:
In a double-blind, placebo-controlled, randomized, parallel study, the behavioral and physiological effects of a single 30-mg dose of oral dextroamphetamine sulfate were measured. Forty patients with a diagnosis of DSM-IV major depressive disorder who were not taking antidepressant medications (22 assigned to dextroamphetamine and 18 to placebo) were compared with 36 control subjects (18 assigned to dextroamphetamine and 18 to placebo) using validated self-report drug effect measurement tools (eg, the Addiction Research Center Inventory), heart rate, and blood pressure.
RESULTS:
Multiple regression analysis showed that severity of depression as measured by the Hamilton Rating Scale for Depression correlated highly with the rewarding effects of dextroamphetamine in the depressed group (model R(2) = 0.63; interaction P =.04). A subsequent analysis categorizing the depressed group into patients with severe symptoms (Hamilton score >23) and those with moderate symptoms revealed a significant interaction between drug and depression (P =.02). Patients with severe symptoms reported rewarding effects 3.4-fold greater than controls.
CONCLUSIONS:
The results suggest the presence of a hypersensitive response is present in the brain reward system of depressed patients, which may reflect a hypofunctional state and may provide a novel pathophysiologic and therapeutic target for future studies.
Learn Faster Today Improve your study skills
Author information
Author/s: Tremblay, Lescia K (LK); Naranjo, Claudio A (CA); Cardenas, Laura (L); Herrmann, Nathan (N); Busto, Usoa E (UE);
Affiliation: Psychopharmacology Research Program, Sunnybrook & Women's College Health Sciences Centre-Sunnybook Campus, University of Toronto, 2075 Bayview Ave, Room F-327, Toronto, Ontario, Canada M4N 3M5.
Journal and publication information
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal: Archives of general psychiatry (Arch Gen Psychiatry), published in United States. (Language: eng)
Reference: 2002-May; vol 59 (issue 5) : pp 409-16
Dates: Created 2002/05/01; Completed 2002/06/06; Revised 2006/11/15;
PMID: 11982444, status: MEDLINE (last retrieval date: 11/6/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
This article has not been indexed for related articles as yet, however you can still use the live related article search links below.
See a large map of 100+ related articles.